CN106676110A - Small interfering ribonucleic acid (siRNA) of long noncoding RNA (lncRNA) ABHD11-AS1 related to ovarian cancer and endometrial cancer, and application of siRNA - Google Patents
Small interfering ribonucleic acid (siRNA) of long noncoding RNA (lncRNA) ABHD11-AS1 related to ovarian cancer and endometrial cancer, and application of siRNA Download PDFInfo
- Publication number
- CN106676110A CN106676110A CN201710089021.9A CN201710089021A CN106676110A CN 106676110 A CN106676110 A CN 106676110A CN 201710089021 A CN201710089021 A CN 201710089021A CN 106676110 A CN106676110 A CN 106676110A
- Authority
- CN
- China
- Prior art keywords
- abhd11
- sirna
- ovarian cancer
- lncrna
- endometrial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010033128 Ovarian cancer Diseases 0.000 title claims abstract description 43
- 206010061535 Ovarian neoplasm Diseases 0.000 title claims abstract description 43
- 108020004459 Small interfering RNA Proteins 0.000 title claims abstract description 26
- 108091046869 Telomeric non-coding RNA Proteins 0.000 title abstract description 14
- 201000004228 ovarian endometrial cancer Diseases 0.000 title abstract 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims abstract description 37
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 3
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 30
- 230000014509 gene expression Effects 0.000 claims description 24
- 108091027963 non-coding RNA Proteins 0.000 claims description 13
- 102000042567 non-coding RNA Human genes 0.000 claims description 13
- 230000002357 endometrial effect Effects 0.000 claims description 12
- 230000002611 ovarian Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 6
- 238000011529 RT qPCR Methods 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 239000003560 cancer drug Substances 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 abstract description 19
- 230000006907 apoptotic process Effects 0.000 abstract description 14
- 206010028980 Neoplasm Diseases 0.000 abstract description 3
- 201000011510 cancer Diseases 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 43
- 210000001519 tissue Anatomy 0.000 description 20
- 230000002018 overexpression Effects 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 108020005198 Long Noncoding RNA Proteins 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 8
- 238000013461 design Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000004696 endometrium Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 108050008874 Annexin Proteins 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 101000883798 Homo sapiens Probable ATP-dependent RNA helicase DDX53 Proteins 0.000 description 1
- 102100038236 Probable ATP-dependent RNA helicase DDX53 Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101710141795 Ribonuclease inhibitor Proteins 0.000 description 1
- 229940122208 Ribonuclease inhibitor Drugs 0.000 description 1
- 102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of oncomolecularbiology, and in particular relates to small interfering ribonucleic acid (siRNA) of long noncoding RNA (lncRNA) ABHD11-AS1 related to ovarian cancer and endometrial cancer, and application of the siRNA. The nucleotide sequences of sense and antisense of the siRNA are respectively GCUACGAGAUCAUGAGCCA and UGGCUCAUGAUCUCGUAGC. The lncRNA is associated with the proliferation and apoptosis abilities of cancer cells, so that the siRNA designed for the lncRNA can be used for preparing medicines for resisting the ovarian cancer and the endometrial cancer.
Description
Technical field
The invention belongs to oncomolecularbiology field, more particularly to a kind of length related to ovarian cancer and carcinoma of endometrium
The siRNA of chain non-coding RNA ABHD11-AS1 and application.
Background technology
Ovarian cancer and carcinoma of endometrium are all one of modal malignant tumor of women, and sickness rate is high, in recent years in rising
Trend, seriously threatens the life and health of China women.Early screening is with timely diagnosis and treatment to ovarian cancer and endometrial carcinoma
Prognosis and curative effect it is most important.It is presently used for the methods for screening and diagnosis index of clinic（Such as CA125）It is still undesirable.
In recent years, long-chain non-coding RNA（long noncoding RNA, lncRNA）Generation, invasion and attack in tumor, turn
Move and the effect in drug resistance, become the study hotspot of pharmaceuticals industry.Long-chain non-coding RNA is a class length more than 200 nucleoside
Acid and the not RNA molecule of coded protein, can be expressed by number of ways and molecular mechanism controlling gene, participate in various biologies
Learn function.The expression of lncRNA and dysregulation are closely related with many malignant tumor, and it is in cell propagation, differentiation and apoptosis
Important function be also gradually proved.With deepening continuously to lncRNA functional studies, lncRNA and tumorigenesis
The research of relation, also achieves the achievement for attracting people's attention.
However, ovarian cancer, the molecular mechanism of endometrium carcinogenesis are unclear, further investigation ovarian cancer, endometrium
The unconventionality expression mechanism of cancer associated gene, it will help its early diagnosis, prevention and treatment, has great importance.
The content of the invention
For the problems referred to above, the present invention provides a kind of long-chain non-coding RNA related to ovarian cancer and carcinoma of endometrium
The siRNA of ABHD11-AS1 and application.The long-chain non-coding RNA is related to the propagation of cancerous cell, apoptosis capacity, for its design
SiRNA can be applicable to the preparation of anti-tumor drug.
To achieve these goals, the present invention provides a kind of long-chain non-coding related to ovarian cancer and carcinoma of endometrium
RNA ABHD11-AS1, its DNA sequence is as shown in SEQ.ID. NO.1；For the siRNA of the long-chain non-coding RNA design, institute
The nucleotide sequence of the sense and antisense of the siRNA for stating is respectively as shown in SEQ.ID.NO.2 and SEQ.ID.NO.3.
SEQ.ID.NO.2 ： GCUACGAGAUCAUGAGCCA.
SEQ.ID.NO.3 ： UGGCUCAUGAUCUCGUAGC.
The siRNA of the described long non-coding RNA related to ovarian cancer and carcinoma of endometrium can be used for preparing anti-ovary
Cancer and endometrial cancer drug.
Beneficial effects of the present invention.
Present invention firstly discovers that expression of the LncRNA ABHD11-AS1 in ovarian cancer and endometrial carcinoma is above
Normal ovarian tissue and endometrial tissue；LncRNA ABHD11-AS1 abnormal expressions and ovarian cancer, the generation of carcinoma of endometrium
It is that the clinical treatment of the LncRNA of ovarian cancer and carcinoma of endometrium and scientific research provide the foundation with the dependency of development.
The LncRNA related to ovarian cancer and carcinoma of endometrium that the present invention is provided, is only by Shanghai SIGMA biotech firms
The Rosetta algorithms of family, it is ensured that design siRNA sequence on efficient Specific basal during gene design；Its plasmid sequence is by reviving
Zhou Jima genes limited company designs.Respectively plasmid vector and si-RNA interference fragments are transfected into into ovarian cancer cell line
In A2780, OVCAR3 and Endometrial carcinoma cell line HEC-1B, Ishikawa, find tumor cell proliferation activity rise/under
Drop, it is taken as that the function of the gene is related to the multiplication capacity of cancerous cell.
Description of the drawings
Fig. 1 detects expressions of the ABHD11-AS1 in ovarian cancer and normal structure using qRT-PCR.
Fig. 2 detects ABHD11-AS1 overexpression/impact of the interference to human epithelial ovarian carcinoma cells proliferation using mtt assay.
Fig. 3 detects ABHD11-AS1 overexpression/impact of the interference to ovarian cellular apoptosis.
Fig. 4 detects the expression feelings in ABHD11-AS1 Endometrial Carcinomas and normal endometrial tissue using qRT-PCR
Condition.
Fig. 5 detects the impact that ABHD11-AS1 overexpression/interference is bred to endometrial carcinoma cell using mtt assay.
Fig. 6 detects ABHD11-AS1 overexpression/impact of the interference to endometrial carcinoma cell apoptosis.
Specific embodiment
With reference to specific embodiment, the present invention is described further.Following examples will be helpful to the present invention's
Understand, but these embodiments, only for being illustrated to the present invention, the present invention is not limited to these contents.Do not make in embodiment
The operational approach of specified otherwise is the art conventional practices.
Embodiment 1.
First, Lnc RNA ABHD11-AS1 are in ovarian cancer tissue, normal ovarian tissue and endometrial, normal-sub
The in utero expression in membrane tissue.
1st, collection of specimens.
In the case where patient knows the inside story, ovarian cancer, normal ovarian tissue and endometrial, normal is gathered in Rhizoma Atractylodis Macrocephalae
Endometrial tissue specimen, it is standby in being stored in liquid nitrogen or -80 DEG C of ultra cold storage freezers after normal saline cleaning；Tissue specimen in
In June, -2016 in June, 2014, in No. 1 Hospital Affiliated to Chinese Medical Univ operating room, gathered by Chen doctor.
2nd, design of primers.
PCR detects the primer.
Forward primer（SEQ.ID.NO.4）：CTCCACCTGACAGCAACATC.
Downstream primer（SEQ.ID.NO.5）：TTCTTGGCAATGGCTTCA.
3rd, detect ABHD11-AS1 in ovarian cancer, normal ovarian tissue and carcinoma of endometrium respectively using qRT-PCR methods
Tissue, the expression of normal endometrial tissue.
3.1st, the tissue specimen Total RNAs extraction collected.
Normal ovarian tissue, ovarian cancer tissue and normal endometrial tissue, endometrial tissue specimen will be collected to use
Trizol soaks, in case extracting total serum IgE；The chloroform of Trizol1/5 volumes is added, acutely vibration 15 seconds, treat that solution is fully newborn
After change, 5 minutes are stored at room temperature；Under the conditions of 4 DEG C, 12,000g centrifugal treating 20 minutes, it is new that Aspirate supernatant is transferred to another
In centrifuge tube, isopyknic isopropanol is added in supernatant, after the centrifuge tube that turns upside down fully is mixed, at 30 DEG C 10 are stood
Minute；Under the conditions of 4 DEG C, 12,000g centrifugal treating 20 minutes, supernatant discarded adds the 75% of lml ethanol along tube wall, up and down
Reverse washing centrifuge tube tube wall, 12,000g centrifugal treating discards ethanol, drying at room temperature precipitation 5-10 after 10 minutes under the conditions of 4 DEG C
Minute, add appropriate（10-20ul）RNase-free water dissolutioies precipitation after, with UV-2800A type ultraviolet-uisible spectrophotometers
Determine RNA concentration and purity（Quantitative RNA concentration 1ug/ul, represents that RNA purity is higher between OD260/OD280 1.8-2.0）.
3.2nd, reverse transcription synthesis cDNA.
Using Promega GoScript reverse transcription systems（A5000、A5001）, inverted according to following operating procedure
The cDNA that record is obtained.
The first step：Take a certain amount of template ribonucleic acid and add primer.
RNA ( 1µg/ul) 5 μl。
Random Primers (0.5 µg /ul) 1 μl。
Oligo(dT)15 Primer (0.5 µg/ul) 1 μl。
The μ l of Nuclease-Free Water (adding to 10 μ l) 3.
Second step：By template ribonucleic acid and reverse transcription primer（Random Primers and Oligo (dT) 15 Primer）'s
Mixture carries out 70 DEG C, 5 min denaturations, after the completion of take out and be placed on ice.
3rd step：RT-Mix is prepared, to each sample cell 10 μ l are added.
Component reverse transcription mixed liquor final concentration.
Nuclease-Free Water 1.6 μl。
GoScript™ 5X Reaction Buffer 4 μl 1X 。
MgCl2 (25 mM) 2 μl 2.5mM 。
PCR Nucleotide Mix 1 μl 0.5mM 。
Recombinant RNasin® Ribonuclease Inhibitor 0.4 μl 20units。
GoScript™ Reverse Transcriptase 1 μl。
4th step：Reverse transcription program, including annealing, extension, reverse transcriptase three steps of inactivation are set（25 DEG C of 5min of annealing, prolong
42 DEG C of 60 min is stretched, 70 DEG C of 15 min, 4 DEG C of+∞ is inactivated.CDNA is obtained after the completion of program.
3.3、Real-time PCR。
（1）By following configuration PCR reaction mixtures（Reactant liquor configuration can be carried out in room temperature）, and point to each reaction tube, so
2ul templates are added afterwards.
Volume components（20ul reaction systems）Final concentration.
Nuclease-Free Water 7 μl 。
Forward primer（10 uM) 0.4ul 0.2uM.
Downstream primer（10 uM) 0.4ul 0.2uM.
GoTaq®qPCR Master Mix,2X 10ul 1X。
CXR 100X 0.2ul 1X。
（2）Using the Real-Time PCR System of ABI PRISM 7500, two-step method enters performing PCR standard amplification journey
Sequence.
（3）Data are derived, Realtime PCR results are analyzed with 2- △ △ CT methods.It is soft using Graphad Prism
Part draws out respectively the chart of ovarian cancer and normal ovarian tissue, carcinoma of endometrium and normal endometrial tissue expression,
As a result such as Fig. 1-3 and Fig. 4；Wherein Fig. 1-1 represents lncRNA ABHD11-AS1 expression in ovarian epithelial carcinoma than in normal ovum
It is significant higher in nest tissue；1-2 represents lncRNA ABHD11-AS1 expression and is proportionate neoplasm staging（Produced according to international woman
Scietific federation（FIGO）Staging System I/II phases and III/IV phases）, 1-3 represents lncRNA ABHD11-AS1 in differentiated journey
Degree group is low compared with low/medium degree differentiation group,*P <0.05；Fig. 4 is represented and compared in lncRNA ABHD11-AS1 expression Endometrial Carcinomas
It is significant in normal endometrial tissue to increase.
LncRNA ABHD11-AS1 described above are related to ovarian cancer, endometrium carcinogenesis, development.
2nd, cell in vitro functional experiment.
1st, Ovarian Cancer Cells A2780, OVCAR3 is purchased from Chinese Academy of Sciences's cell bank, and Endometrial carcinoma cell line HEC-1B is purchased from
Chinese Academy of Sciences's cell bank, cell culture medium DMEM/RPMI 1640 and hyclone are purchased from HyClone companies, ABHD11-AS1 matter
Grain expression vector is purchased from Suzhou Ji Ma Technology Co., Ltd., and siRNA interference fragments sequence is synthesized by Shanghai SIGMA biotech firms,
RNA extraction agent RNAiso Plus are purchased from precious biological engineering company limited, Reverse Transcriptase kit High Capacity cDNA
Reverse Transcription Kits are purchased from Invitrogen companies, quantitative PCR kit Power SYBR Green
PCR Master Mix are purchased from Invitrogen companies, and ABHD11-AS1 genes and house-keeping gene 18S primers are by Shanghai life work life
Thing engineering services company limited synthesizes.
1.1st, cell culture：Ovarian cancer and the endometrial carcinoma cell hyclone cell culture medium for containing 10%, in 37
DEG C, 5%CO2Incubator in cultivate, using ABHD11-AS1 gene RNAs interference and overexpression plasmid transfection ovarian cancer cell line
A2780, OVCAR3 and Endometrial carcinoma cell line HEC-1B, according to lipo2000 description respectively by ABHD11-AS1's
SiRNA and ABHD11-AS1 plasmids are proceeded in cell, are cultivated.
2nd, Guo Biao Da ∕ jamming effectivenesss detection：Transfection efficiency result using QRT-PCR detect, jamming effectiveness more than 50%,
Overexpression efficiency is more than 5 times.
2.1st, cross table carries out cell proliferation experiment up to after ∕ interference ABHD11-AS1（MTT）.
Proliferation experiment：Choose ABHD11-AS1 Guo Biao Da ∕ interference in cell line and, as experimental group, transfect the cell of empty carrier
As a control group, cell counting is carried out, by cell kind to 96 orifice plates, often 3000, hole cell, plus 100ul culture fluid is distinguished
It is little in 37 DEG C of incubations 4 after adding within 24,48,72 hours the mg/mL MTT Solution Cells incubators of 20ul 5 incubation 2-4 hours in 0
When, supernatant is discarded, 150ul DMSO are added, OD values are surveyed under 490nm using spectrophotometer, disposal data is depicted as folding
Line chart, is shown in Fig. 2 and Fig. 5.
2.1.1, the ovarian cancer cell line and Endometrial carcinoma cell line cell proliferation experiment after overexpression ABHD11-AS1
As a result, Fig. 2-1 to Fig. 2-4 and Fig. 5-1 is seen；Wherein Fig. 2-1 to Fig. 2-2 is represented in ovarian cancer A2780 and OVCAR3 cell transfers
Dye ABHD11-AS1 plasmids, its expression is raised；Fig. 2-3 to Fig. 2-4 represents that ABHD11-AS1 expression is raised, ability of cell proliferation
Significantly increase；Wherein Fig. 5-1 represents the expression that transfection ABHD11-AS1 plasmids are improved in its Endometrial Carcinomas cell.
It can be seen that, after overexpression ABHD11-AS1 genes, ovarian cancer and endometrial carcinoma cell multiplication capacity strengthen.
2.1.2, the ovarian cancer cell line and endometrial carcinoma cell cell proliferation experiment result after ABHD11-AS1 interference
Fig. 2-5 to 2-8 and Fig. 5-2 is seen to Fig. 5-4, wherein Fig. 2-5 to Fig. 2-6 represents ovarian cancer cell line transfection si-ABHD11-AS1
Reduce its expression；Fig. 2-7 to Fig. 2-8 represents silence ABHD11-AS1, and cell proliferation ability is decreased obviously；Fig. 5-2 is represented and utilized
SiRNA can be in silence its Endometrial Carcinomas cell expression；Fig. 5-3 represents that ABHD11-AS1 expression increases, cell propagation
Ability is significantly improved；Fig. 5-4 represents silence expression, and ability of cell proliferation is suppressed.
It can be seen that, interference is fallen after ABHD11-AS1 genes, and ovarian cancer and endometrial carcinoma cell multiplication capacity decline.
2.2nd, cell apoptosis assay after Gan Rao ∕ overexpression ABHD11-AS1.
By cell in 6cm disk cultures before experiment, (ABHD11-AS1 gene RNAs are disturbed or overexpression matter to add process factor
Grain) transfection 48 hours after, tested.Cell is collected with EDTA trypsinizations, 1500r centrifugal treating is not contained after 5 minutes
Cell, the PBS of pre-cooling is washed twice, and after centrifugation, collects cell about 5 × 10 5It is individual, 1 × Binding Buffer are added, it is resuspended thin
Born of the same parents 100ul, adds 5 μ L Annexin V-FITC and 5uL PI Staining Solution (interference) or 5 μ L Annexin
V-7AAD and 5uL PE Staining Solution（Height expression）, gently mixing, room temperature lucifuge is incubated 10 minutes, adds
400 μ L 1 × Binding Buffer, gently mix；Sample was detected in 1 hour in-flow cell instrument.
2.2.1, the ovarian cancer cell line and Endometrial carcinoma cell line cell apoptosis assay after overexpression ABHD11-AS1
As a result see Fig. 3-1 to 3-2 and Fig. 6-1；Wherein Fig. 3-1 to Fig. 3-2 represents that ABHD11-AS1 expression rises, ovarian cellular apoptosis
Ratio is decreased obviously；Fig. 6-1 represents in Endometrial Carcinomas cell line that ABHD11-AS1 expression is raised, and apoptosis ratio is bright
It is aobvious to decline.
It can be seen that, after overexpression ABHD11-AS1 genes, ovarian cancer and endometrial carcinoma cell apoptosis capacity weaken.
2.1.2, the ovarian cancer cell line and Endometrial carcinoma cell line apoptosis experimental result after ABHD11-AS1 interference is shown in
Fig. 3-3 to 3-4 and Fig. 6-2；Wherein Fig. 3-3 to Fig. 3-4 represents that using the expression of siRNA silences ABHD11-AS1 ovarian cancer is thin
Born of the same parents system apoptosis rate increases notable；Fig. 6-2 represents that silence ABHD11-AS1 remarkably promotes endometrial carcinoma cell apoptosis.
It can be seen that, interference is fallen after ABHD11-AS1 genes, and ovarian cancer and endometrial carcinoma cell apoptosis capacity increase.
Sequence table
The ＞ No. 1 Hospital Affiliated to Chinese Medical Univ of ＜ 110
A kind of siRNA of long-chain non-coding RNA ABHD11-AS1s related to ovarian cancer and carcinoma of endometrium of the ＞ of ＜ 120 and should
With
The ＞ 5 of ＜ 160
The ＞ 1 of ＜ 210
The ＞ 1660 of ＜ 211
The ＞ DNA of ＜ 212
The nucleotide sequence of the ＞ long-chain non-coding RNA ABHD11-AS1 of ＜ 213
The ＞ 1 of ＜ 400
ctcgagtgaa gacggaaatg gggcggggct gcgagctagg gcgggagaag gagcgcgggg aggacgtacc 70
ttgtgagatg cgagccggcc aacagcttgc aagcatgctc cgctggaccc gagcctggag gctcccgcgt 140
gagggactcg gcccccacgg ccctagcttc gcgagggtgc ctgtcgcacc cagcagcagc agcggcggcc 210
gagggggcgc cgagccgagg ccgcttccgc tttcctacag gcttctggac ggggaggcag ccctcccggc 280
cgtcgtcttt ttgcagggct cttcggcagc aaaactaact tcaactccat cgccaagatc ttggcccagc 350
agacaggccg tgctgacggt ggatgctcgt aaccacggtg acagccccca cagcccagac atgagctacg 420
agatcatgag ccaggacctg caggaccttc tgccccagct gggcctggtg ccctgcgtcg tcgttggcca 490
cagcatggga ggaaagacag ccatgctgct ggcactacag agggtgagcc gcccatgtct ggggcctcct 560
cccattcagt atataccctg agggccctgc aggcaacctg ggactcacat gatcgttgga tgaccaagtt 630
caggctccag gagccatgcc tgagactccc tatgtctgcc taagactggt cccagttcgg ttctctccca 700
cagccagagc tggtggaacg tctcattgct gtagatatca gcccagtgga aagcacaggt gtctcccact 770
ttgcaaccta tgtggcagcc atgagggcca tcaacatcgc agatgagctg ccccgctccc gtgcccgaaa 840
actggcggat gaacagctca gttctgtcat ccaggacatg gccgtgcggc agcacctgct cactaacctg 910
gtagaggtag acgggcgctt cgtgtggagg gtgaacttgg atgccctgac ccagcaccta gacaagatct 980
tggctttccc acagaggcag gagtcctacc tcgggccaac actctttctc cttggtggaa actcccagtt 1050
cgtgcatccc agccaccacc ctgagattat gcggctcttc cctcgggccc agatgcagac ggtgccgaac 1120
gctggccact ggatccacgc tgaccgccca caggacttca tagctgccat ccgaggcttc ctggtctaag 1190
agttgctggc aagaagatgg ccgggcgtgg tggctcatgc ctgtaattcc agcactttgg gaggctaagg 1260
cgggaggatg acttgaggcc aggagttgga gaccagcctg gccaacatgg tgaaaccctg tctctactaa 1330
aaatacaaaa attagcctgg cgtggtggtg cacacctgta atcccagcta ctctggaggc tgaggcagga 1400
gaatcacttg aaccctggag gcagaggttg caatgagccg agatcacacc actacactcc agcctaggca 1470
acagagcaag actctgtctc aaaaaaaaca aaacaaaaag gaggcacaaa accccaggct tcaagtctct 1540
gcagcctgct ccacatttgg gcacagaagg actcagacag gcactgtgtg ggcacgaggt tttacagggg 1610
tggtcagacc tcaggcttta atgaataaag acactactcc caaaggtacc 1660
The ＞ 2 of ＜ 210
The ＞ 19 of ＜ 211
The ＞ RNA of ＜ 212
The ＞ outer primer sense of ＜ 213
The ＞ 2 of ＜ 400
gcuacgagau caugagcca 19
The ＞ 3 of ＜ 210
The ＞ 19 of ＜ 211
The ＞ RNA of ＜ 212
The ＞ outer primer antisense of ＜ 213
The ＞ 3 of ＜ 400
uggcucauga ucucguagc 19
The ＞ 4 of ＜ 210
The ＞ 20 of ＜ 211
The ＞ DNA of ＜ 212
The ＞ artificial sequences of ＜ 213
The ＞ 4 of ＜ 400
ctccacctga cagcaacatc 20
The ＞ 5 of ＜ 210
The ＞ 18 of ＜ 211
The ＞ DNA of ＜ 212
The ＞ artificial sequences of ＜ 213
The ＞ 5 of ＜ 400
ttcttggcaa tggcttca 18
Claims (4)
1. a kind of siRNA of the long-chain non-coding RNA ABHD11-AS1 related to ovarian cancer and carcinoma of endometrium, its feature exists
In the nucleotide sequence of the sense and antisense of described siRNA is respectively such as SEQ.ID.NO.2 and SEQ.ID.NO.3 institutes
Show：
SEQ.ID.NO.2 ： GCUACGAGAUCAUGAGCCA；
SEQ.ID.NO.3 ： UGGCUCAUGAUCUCGUAGC.
2. the siRNA of long-chain non-coding RNA ABHD11-AS1 as claimed in claim 1, it is characterised in that apply qRT-PCR
Method detects respectively ABHD11-AS1 in ovarian cancer, normal ovarian tissue and endometrial, normal endometrial tissue
Expression.
3. the siRNA of long-chain non-coding RNA ABHD11-AS1 as claimed in claim 1, it is characterised in that described qRT-
PCR method detection primer nucleotide sequences used are respectively：Forward primer（SEQ.ID.NO.4）：
CTCCACCTGACAGCAACATC；Downstream primer（SEQ.ID.NO.5）：TTCTTGGCAATGGCTTCA.
4. the siRNA of long-chain non-coding RNA ABHD11-AS1 as claimed in claim 1 is used to prepare ovarian cancer resistance and uterus
Inner membrance cancer drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710089021.9A CN106676110B (en) | 2017-02-20 | 2017-02-20 | The siRNA of long-chain non-coding RNA ABHD11-AS1 relevant to oophoroma and carcinoma of endometrium a kind of and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710089021.9A CN106676110B (en) | 2017-02-20 | 2017-02-20 | The siRNA of long-chain non-coding RNA ABHD11-AS1 relevant to oophoroma and carcinoma of endometrium a kind of and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106676110A true CN106676110A (en) | 2017-05-17 |
| CN106676110B CN106676110B (en) | 2019-11-05 |
Family
ID=58861107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710089021.9A Expired - Fee Related CN106676110B (en) | 2017-02-20 | 2017-02-20 | The siRNA of long-chain non-coding RNA ABHD11-AS1 relevant to oophoroma and carcinoma of endometrium a kind of and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106676110B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107354159A (en) * | 2017-08-03 | 2017-11-17 | 哈尔滨医科大学 | Applications of the long-chain non-coding RNA SMAD5 AS1 siRNA in treatment of ovarian cancer |
| US10851376B2 (en) | 2018-12-28 | 2020-12-01 | The Florida International University Board Of Trustees | Long noncoding RNAs in pulmonary airway inflammation |
| CN113234824A (en) * | 2021-05-07 | 2021-08-10 | 复旦大学附属妇产科医院 | Application of RP11-379k17.4 overexpression in preparation of endometrial cancer treatment drug |
-
2017
- 2017-02-20 CN CN201710089021.9A patent/CN106676110B/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| CHEN M ET AL.: "Increased lncRNA ABHD11-AS1 represses the malignant phenotypes of bladder cancer", 《ONCOTARGET》 * |
| YANG Y ET AL.: "Using gastric juice lncRNA-ABHD11-AS1 as a novel type of biomarker in the screening of gastric cancer", 《TUMOR BIOLOGY》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107354159A (en) * | 2017-08-03 | 2017-11-17 | 哈尔滨医科大学 | Applications of the long-chain non-coding RNA SMAD5 AS1 siRNA in treatment of ovarian cancer |
| CN107354159B (en) * | 2017-08-03 | 2021-05-25 | 哈尔滨医科大学 | Application of siRNA of long-chain non-coding RNA SMAD5-AS1 in ovarian cancer treatment |
| US10851376B2 (en) | 2018-12-28 | 2020-12-01 | The Florida International University Board Of Trustees | Long noncoding RNAs in pulmonary airway inflammation |
| CN113234824A (en) * | 2021-05-07 | 2021-08-10 | 复旦大学附属妇产科医院 | Application of RP11-379k17.4 overexpression in preparation of endometrial cancer treatment drug |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106676110B (en) | 2019-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106676110A (en) | Small interfering ribonucleic acid (siRNA) of long noncoding RNA (lncRNA) ABHD11-AS1 related to ovarian cancer and endometrial cancer, and application of siRNA | |
| CN106834292B (en) | The shRNA of cyclic annular non-coding RNA-PUM1 relevant to oophoroma a kind of and application | |
| CN107519193B (en) | Molecular diagnostic marker for early stage esophageal squamous carcinoma and application thereof | |
| CN107586842A (en) | A kind of biomarker for clear cell carcinoma of kidney diagnosis and treatment | |
| CN106801057B (en) | The siRNA of long-chain non-coding RNA PCGEM1 relevant to oophoroma and carcinoma of endometrium a kind of and application | |
| CN111647660B (en) | Application of Linc01559 in diagnosis and treatment of gastric cancer | |
| CN106086017A (en) | ENST00000509938.1 and preparation or diagnostic agent or medicine or test kit and application | |
| CN102936629B (en) | Method and composition based on tiny RNA for liver cirrhosis and early liver cancer diagnosis | |
| CN109486816B (en) | Polynucleotide for treating tumor and its application | |
| CN110923324A (en) | Breast cancer miRNA marker and application thereof | |
| CN110317878A (en) | A kind of long-chain non-coding RNA and its application for bladder cancer diagnosis and treatment monitoring | |
| CN106167822A (en) | A kind of long-chain non-coding RNA and application thereof | |
| CN111808861B (en) | Application of lncRNA in umbilical blood mesenchymal stem cell apoptosis caused by oxidative stress | |
| CN102586237A (en) | Poly-nucleic acid molecule and application thereof | |
| CN112941183B (en) | Application of non-coding gene miR-187-5p in primary liver cancer diagnosis and treatment | |
| CN106906215A (en) | A kind of siRNA of long-chain non-coding RNA TDRG1 related to oophoroma and carcinoma of endometrium and application | |
| CN110946872B (en) | Application of miR-4491 in preparation of medicine for treating breast cancer | |
| CN110257522A (en) | Gene hsa_circ_0045881 relevant to breast cancer diagnosis and treatment and its application | |
| CN109679960A (en) | It is a kind of adjust hepatocyte growth new gene RGD1559786 siRNA and its application | |
| CN113373151B (en) | Application of annular RNAhsa _ circ _0008399 | |
| CN113388673B (en) | Application of long noncoding RNA CARMEN | |
| CN114958856B (en) | Application of long-chain non-coding RNA CYP1B1-AS1 AS breast cancer biomarker and treatment target | |
| CN111118139B (en) | Molecular target for osteoporosis and application thereof | |
| CN108753973B (en) | Application of long-chain non-coding RNA and biological product | |
| CN108315417A (en) | Pass through the kit of miR-124-3p and GATA3-AS1 joint-detections gastric cancer in blood |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20191105 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |